US biopharmaceutical firm Aimmune has revealed that its peanut allergy candidate AR101 hit its primary endpoint in the largest trial of its kind, proving that around two-thirds of patients were are able to tolerate at least 600mg of peanut protein – equal to about two average peanut kernels – after taking the drug.
Aimmune’s peanut allergy candidate hits main endpoint at Phase 3
